Anti-HIV treatments have been very successful in suppressing viral load in HIV-infected patients. However, new therapeutic strategies are needed to circumvent the inevitable selection of viruses that are resistant to all currently used drugs. Of the 32 drugs approved for the treatment of HIV infection, only two block viral entry, and there are no approved drugs that target the HIV surface glycoprotein gp120. KD-247 is a promising humanized monoclonal antibody (mAb) that has been developed by collaborator Dr. Shuzo Matsushita and colleagues. It binds the V3 loop of gp120 and neutralizes extremely potently a broad panel of diverse clade B HIV-1 isolates. Moreover, KD-247 suppresses replication of viral strains that are resistant to all currently approved drugs. Based on its promising properties, KD-247 has entered Phase Ib clinical trials for the treatment of HIV-1 infections. However, KD-247 like other anti-V3 antibodies lacks cross- clade neutralization ability. The structural basis for the clade specificity of KD-247 is unclear. This proposal will focus on the use of structure-based design to construct second generation single-chain variable fragments (scFvs) of KD-247 with broader clade specificity. In preliminary results, we have solved the crystal structure of the unliganded antigen-binding fragment (Fab) of KD-247 at the highest resolution (1.55 E) reported for any humanized antibody to date. We have also obtained a cloned scFv based on wild-type KD-247 to be used for the construction of mutants and performed molecular modeling studies that will initially guide the selection of scFv mutations. We propose to extend these studies to pursue the following specific aims: 1. To determine why KD-247 neutralizes efficiently a broad spectrum of clade B isolates 2. To design, construct, and evaluate scFv KD-247 that effectively bind clade B AND non-clade B isolates Achieving the aims of this proposal will provide structural, biochemical, and virological knowledge that will direct the design and engineering of second generation anti-V3 antibodies with improved potency and broader neutralization ability. In addition, our expected high-resolution structures will also provide essential information about molecular protein-protein contacts important for antibody recognition of specific antigens. Structure-based anti-HIV mAb engineering is an innovative approach that can serve as a paradigm for the design of additional therapeutics.

Public Health Relevance

This project will determine crystal structures of KD-247, a monoclonal antibody currently in clinical trials, that will help us understand why it works well with many, but not all types of HIV. This knowledge will help us design second generation antibodies with broader neutralization ability.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI094715-02
Application #
8137775
Study Section
AIDS Molecular and Cellular Biology Study Section (AMCB)
Program Officer
Conley, Tony J
Project Start
2010-09-10
Project End
2013-08-31
Budget Start
2011-09-01
Budget End
2013-08-31
Support Year
2
Fiscal Year
2011
Total Cost
$187,481
Indirect Cost
Name
University of Missouri-Columbia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
153890272
City
Columbia
State
MO
Country
United States
Zip Code
65211
Kirby, Karen A; Ong, Yee Tsuey; Hachiya, Atsuko et al. (2015) Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247. FASEB J 29:70-80
Adedeji, Adeyemi O; Severson, William; Jonsson, Colleen et al. (2013) Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol 87:8017-28
Hachiya, Atsuko; Reeve, Aaron B; Marchand, Bruno et al. (2013) Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral Drugs. Antimicrob Agents Chemother 57:4554-4558
Izumi, Kazuki; Kawaji, Kumi; Miyamoto, Fusasko et al. (2013) Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design. Int J Biochem Cell Biol 45:908-15
Sohl, Christal D; Singh, Kamlendra; Kasiviswanathan, Rajesh et al. (2012) Mechanism of interaction of human mitochondrial DNA polymerase ? with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity. Antimicrob Agents Chemother 56:1630-4
Kirby, Karen A; Marchand, Bruno; Ong, Yee Tsuey et al. (2012) Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase. Antimicrob Agents Chemother 56:2048-61
Adedeji, A O; Singh, K; Sarafianos, S G (2012) Structural and biochemical basis for the difference in the helicase activity of two different constructs of SARS-CoV helicase. Cell Mol Biol (Noisy-le-grand) 58:114-21
Ong, Y T; Kirby, K A; Hachiya, A et al. (2012) Preparation of biologically active single-chain variable antibody fragments that target the HIV-1 gp120 V3 loop. Cell Mol Biol (Noisy-le-grand) 58:71-9
Hachiya, Atsuko; Marchand, Bruno; Kirby, Karen A et al. (2012) HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors. J Biol Chem 287:29988-99
Ndongwe, Tanyaradzwa P; Adedeji, Adeyemi O; Michailidis, Eleftherios et al. (2012) Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase. Nucleic Acids Res 40:345-59

Showing the most recent 10 out of 17 publications